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Abstract 
The effects of vanadate and the stable peroxovanadate compound bpV(pic) on insulin binding and degradation were investigated in rat 
adipocytes under conditions of ongoing receptor cycling. Both bpV(pic) and vanadate increased 12sI-insulin binding to intact cells through 
an increase in apparent receptor affinity. The maximal effect of bpV(pic) was to increase binding ~ 4-fold (ECso 0.06 + 0.01 mM), 
whereas vanadate increased binding ~ 2-fold (ECso 1.4 + 0.2 mM). Removal of cell surface insulin-receptor complexes with trypsin 
showed that the effects on binding exerted by bpV(pic) and vanadate were due to a similar increase in both cell surface binding and 
intracellular accumulation f radioactivity. Both bpV(pic) and vanadate inhibited the degradation of 125I-insulin i  medium containing 1% 
bovine serum albumin. The ratio of degraded/intact in racellular 125I-insulin was also markedly reduced by these agents, suggesting that 
they inhibit intracellular insulin-degrading proteases. Similar to previous findings with vanadate, bpV(pic) stimulated glucose transport 
and, at low concentrations, enhanced insulin sensitivity. Taken together, these data demonstrate hat both bpV(pic) and vanadate inhibit 
insulin degradation. In addition, they significantly enhance cell surface insulin binding in rat fat cells and this is associated with an 
improved insulin sensitivity. 
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1. Introduction 
Various vanadate compounds have been found to have 
insulinomimetic effects both in vitro and in vivo [1-8]. 
This has been demonstrated in normal as well as in 
insulin-resistant s ates including diabetes [9-13]. Despite 
extensive research, the mechanisms for the insulin-like 
action of vanadium compounds are only partly understood. 
It is clear that they inhibit phosphotyrosine phosphatases 
and considerable vidence suggests that activation of the 
insulin receptor tyrosine kinase may be involved [14-18], 
although tyrosine-kinase-independent effects of vanadate 
have also been reported 1[19]. Recently, it was proposed 
that vanadate stimulates a cytosolic tyrosine kinase [20]. 
Abbreviations: BSA, bovine serum albumin; IGF-II, insulin-like 
growth factor II; MHC-I, major histocompatibility complex class I anti- 
gen; PEG, polyethyleneglycol; pV, peroxovanadate; PTP, phospho- 
tyrosine phosphatase; TCA, trichloroacetic a id. 
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This concept is supported by the finding that vanadate can 
elicit a full stimulatory action on glucose transport in 
adipocytes depleted of cell-surface insulin receptors [21]. 
Peroxides of vanadium, peroxovanadates (pVs), are more 
potent insulin mimickers in rat adipocytes than vanadate 
[14,15] and, in contrast o vanadate, are also effective in 
human fat cells [22]. pVs are also much more potent 
phosphotyrosine phosphatase (PTP) inhibitors than vana- 
date [14,23]. 
Fantus et al. [24] have reported that vanadate can 
increase insulin binding due to an enhanced insulin recep- 
tor affinity. Moreover, previous work in our laboratory 
demonstrated a rapid and marked increase in the number 
of cell-surface insulin receptors both in normal and in- 
sulin-resistant rat adipocytes following vanadate treatment 
[6,12]. This effect is associated with the ability of vanadate 
to improve insulin sensitivity in rat adipocytes [6,12]. In 
the present work, we studied the effects of vanadate and 
bpV(pic) on insulin binding to intact rat fat cells and 
partially purified insulin receptors as well as on internal- 
ization of the insulin-receptor complexes and insulin 
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degradation. The stable and well-characterized peroxo- 
vanadate compound, potassium bisperoxopicolinatooxo- 
vanadate (bpV(pic)), was used as a representative pV 
compound [23]. 
the cell surface receptors, thus allowing measurement of
intracellularly accumulated radioactivity. 
2.4. Partial purification of insulin receptors and subse- 
quent 1251-insulin binding 
2. Materials and methods 
2.1. Materials 
Human monocomponent insulin and mono-[~25I]Tyr - 
A 14-insulin (spec. act. 200-300 /.tCi//xg) were purchased 
from Novo Nordisk (Copenhagen, Denmark). [14C]3-O-D- 
methylglucose (spec. act. 59 /zCi/~mol) and 3-[125 I]Tyr - 
insulin-like growth factor II (IGF-II; spec. act. 263 
/zCi//xg) were from Amersham (Amersham, Bucks., UK). 
Collagenase was from Boehringer Mannheim GmbH 
(Mannheim, Germany) and bovine serum albumin (BSA; 
fraction V), wheat germ agglutinin (WGA), trypsin, baci- 
tracin and sodium orthovanadate (Na3VO 4) were from 
Sigma Chemicals (St. Louis, MO, USA). A peptide made 
against he major histocompatibility complex class I anti- 
gen (MHC-I), DK69-85, was kindly donated by Dr. L. 
Olsson (Receptron, San Francisco, CA, USA). Medium 
199 was obtained from Gibco BRL, Life Technologies 
(Paisley, UK). The peroxovanadium compound, bpV(pic), 
was prepared as previously reported [23] and was kindly 
provided by Dr. Alan Shaver (Department of Chemistry, 
McGill University, Montreal, Canada). 
2.2. Isolation of adipocytes 
Male Sprague-Dawley rats, weighing 150-200 g and 
fed ad libitum, were stunned and decapitated. The epididy- 
mal fat pads were instantly excised and minced. Fat cells 
were isolated in medium 199 containing 0.6 mg/ml colla- 
genase at 37°C for 1 h in a shaking water bath (~ 120 
rpm) as previously described [6]. 
2.3. ~25I-insulin binding to intact cells 
After washing, the cells (lipocrit 5-10%) were incu- 
bated with the indicated concentrations of vanadate, 
bpV(pic), bacitracin and 125I-insulin (0.2 ng/ml) at 37°C 
for 60 min in a shaking water bath (~ 120 rpm). The BSA 
concentration i the medium was 4%, unless otherwise 
specified. The cells and medium were separated by centrif- 
ugation through dinonyl phtalate and 125I-insulin binding 
to cells was measured as cell-associated radioactivity. 
Non-specific binding, defined as binding in the presence of 
3.5 /xg/ml unlabeled insulin, was subtracted. In some 
experiments, 2 mM KCN was added to the medium for 5 
min after the incubation with x25I-insulin and bpV(pic) or 
vanadate in order to deplete the cells of ATP [25] and stop 
receptor recycling. The cells were then transferred to 16°C 
and 1 mg/ml of trypsin was added for 15 min to remove 
The procedure followed was essentially as described by 
Zick et al. [26]. Aliquots of the cell suspension were 
treated with 0.5% Triton X-100 in Hepes buffer (50 mM, 
pH 7.4), containing 10 mM MgSO 4 and protease inhibitors 
(leupeptin 1 mg/1, pepstatin 1 mg/1, phenyl methyl- 
sulphonylfluoride 5 mg/ l  and aprotinin 1.2 mg/1). Fol- 
lowing vortex-mixing and freezing at -80°C for 1 h, the 
cell suspension was thawed and homogenized 10 times at 
4°C. After centrifugation at 17000×g for 15 min at 
-4°C, the triglyceride layer was carefully removed and 
the infranatant centrifuged at 100000 × g for 60 min. The 
supernatant was applied to a WGA-agarose column and 
allowed to recirculate three times. After careful washing, 
the purified insulin receptors were eluted with 0.3 M 
N-acetylglucosamine  Hepes buffer. Insulin binding was 
determined by adding 2 ng/ml 125I-insulin to the eluate. 
After 18 h at 4°C the receptors were precipitated with 30% 
polyethyleneglycol using 10% IgG as carrier and specific 
binding was measured. 
2.5. Degradation of lesl-insulin 
Cells were incubated at 37°C for 1 h as described above 
in the presence of 12sI-insulin (0.2 ng/ml) and the indi- 
cated concentrations of vanadate, bpV(pic) or bacitracin. 
At the end of the incubation period, the cells were re- 
moved by centrifugation through dinonyl phtalate and 100 
/xl of the cell-free medium was added to 1 ml of 10% 
trichloroacetic acid (TCA) and the mixture centrifuged. 
The pellet was extensively washed with 10% TCA. The 
radioactivity in the pellet and supernatant were considered 
to represent intact and degraded insulin, respectively 
[27,28]. In some experiments, the cell suspension was first 
incubated with medium containing 1% BSA for the indi- 
cated time at 37°C. The incubation medium was then 
separated from the cells by centrifugation and 0.2 ng/ml 
of 125I-insulin added to the cell-free medium with or 
without bpV(pic) or vanadate. The incubation was then 
performed for 1 h at 37°C and the degradation of ~25I-in- 
sulin in the medium measured as described above. 
To quantify degraded and intact insulin in the intra- 
cellular compartment, the cell suspension was incubated 
with 0.2 ng/ml of 12sI-insulin and various concentrations 
of bpV(pic) or vanadate at 37°C for 1 h. Then, 2 mM of 
KCN was added for another 5 min and the cell suspension 
transferred to 16°C, trypsin (1 mg/ml) added for 10 min 
followed by the addition of 2 mg/ml of trypsin inhibitor. 
The cells were washed three times with fresh medium to 
remove radioactivity outside the cell. Cells were then 
separated from medium, solubilized in 0.2 ml of Hepes 
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buffer (50 mM, pH 7.4) containing 2% Triton X-100, 10 
mM MgSO 4 and also protease inhibitors, 5% BSA and 1 
mg/ml  bacitracin which were used to prevent further 
degradation of insulin during the solubilization. The solu- 
bilized cells were centrifuged in 10% TCA as described 
above to determine the degraded and intact intracellular 
125I-insulin, respectively. 
2.6. [14 C]3-O-methylglucose transport 
These experiments were essentially performed accord- 
ing to the method of Whitesell and Gliemann [29]. Briefly, 
after preincubating cells with the indicated agents, aliquots 
of the cell suspension wen~ pulsed with [~4C]3-0-D-methyl- 
glucose (50 /zM, 1.0 /xC i ) for  5 s. 3-0-methylglucose 
uptake was stopped by adding ice-cold phloretin (0.3 M). 
Cell-associated radioactivity was measured and adjusted 
for extracellularly trapped [14C]3-0-methylglucose (sub- 
traction of cell-associated radioactivity obtained when 
tracer was added after phloretin). 
2.7. Statistics 
Statistical significance of differences was tested with 
Student's two-tailed t-test for paired data. Results are 
means 5- S.E.M. unless otherwise indicated. 
3. Resu l ts  
3.1. ~25I-insulin binding to intact cells 
Fig. 1 shows that rat adipocytes incubated with bpV(pic) 
at 37°C displayed a markedly increase in cell-associated 
~25I-insulin compared to untreated cells. The maximal 
effect of bpV(pic) was to increase binding ~ 4-fold and 
ECs0 was 0.06 5-0.01 mM (n = 6). However, this effect 
disappeared at high concentrations of bpV(pic) (above 1 
mM) and was completely lost at 10 mM. Scatchard analy- 
sis showed that the enhancement of insulin binding pro- 
duced by bpV(pic) (0.5 mM) was due to an increase in 
apparent affinity (apparent Kd:168 5- 28 ~U/ml  vs 48 5- 4 
~U/ml  for control and bpV(pic) treatment, respectively, 
n = 4, P < 0.05) without any clear change in the number 
of binding sites (Fig. 1, inset). Vanadate exerted a smaller 
enhancement of insulin binding (about 2-fold increase) and 
the concentration required (ECs0 1.4 5- 0.2 mM; n = 3) 
was ~ 20 times higher than that for bpV(pic) (data not 
shown). Incubation with bacitracin (1 mg/ml )  under the 
same conditions increased cell-associated 125I-insulin about 
75% (data not shown). 
Cells which were pretreated for 5 min with 30 /xM of a 
peptide fragment derived from the MHC-I  molecule, which 
completely blocks insulin receptor internalization [30], also 
showed enhanced insulin binding (~ 3-fold) in the pres- 
ence of 0.5 mM bpV(pic) (data not shown). 
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Fig. 1. Effects of bpV(pic) on ]2~I-insulin binding to intact adipocytes. 
Cells were incubated with 0.2 ng/ml J25I-insulin in medium containing 
4% BSA and different concentrations of bpV(pic) at 37°C for 60 min. 
Total cell-associated ra ioactivity was then determined. Data are means _+ 
S.E.M. of 6 separate experiments (* P < 0.05; * * P < 0.01; * * * P < 
0.001). The inset in Fig. l shows a Scatchard plot. Cells were incubated 
with 0.2 ng/ml 1251-insulin at37°C for 60 rain together with different 
concentrations of unlabelled insulin in the presence (O) or absence (©) 
of 0.5 mM bpV(pic). The results are from one representative experiment 
repeated four times. 
3.2. Cellular distribution of bound 125I-insulin and insulin 
receptors 
To determine the effects of bpV(pic) and vanadate on 
binding of ~25I-insulin to the cell-surface and cell-interior, 
trypsin was used to remove the insulin-receptor complexes 
at the cell surface. Following a 60-min incubation with 
tracer at 37°C, receptor cycling was stopped by treating the 
cells with KCN and trypsin was then added, bpV(pic) in 
the concentration range up to ~ 0.5 mM raised the propor- 
tion of intracellular adioactivity from ~ 38% to ~ 56% 
of total cell-associated binding (Fig. 2). Vanadate xerted a 
similar effect but, again, required ~ 20-fold higher con- 
centrations (data not shown). 
Experiments with ]zsI-insulin binding to solubilized 
cells performed as previously described [6] showed that 
insulin binding to the total pool of cellular receptors or the 
intracellular receptors was not significantly altered by 
preincubating the cells with either bpV(pic) (0.1 mM) or 
vanadate (4 mM) (data not shown). 
3.3. Direct effects of bpV(pic) and vanadate on insulin-re- 
ceptor binding 
The cells were pretreated with 2 mM KCN at 37°C for 
5 min to stop receptor internalization and recycling. Then, 
125I-insulin binding to cell surface receptors was carried 
out at 16°C for 1 h in the presence of bpV(pic) or 
vanadate, bpV(pic) increased binding (by 60 + 13%, n = 6, 
P < 0.001) and Scatchard analysis again indicated an in- 
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Fig. 2. Effects of bpV(pic) on the cellular distribution of 125I-insulin 
binding. Cells were incubated with I25I-insulin and bpV(pic) as stated in 
Fig. 1. After the incubation, 2 mM KCN was added for 5 min and the 
cells were then transferred to 16°C and treated with trypsin (1 mg/ml)  
for 15 min. The cell-associated radioactivity was subsequently deter- 
mined. Data represent intracellular radioactivity expressed as % of total 
(without trypsin) and are means_ S.E.M. of 3-5 separate xperiments 
(* P < 0.05). 
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Fig. 3. Effects of bpV(pic) and vanadate on insulin degradation. I25I-in- 
sulin (0.2 ng/ml)  was added to adipocytes in medium containing 1% 
BSA in the presence of bpV(pic) (0 )  or vanadate (O) at 37°C for 1 h, 
After separation of cells and medium, the degraded 125I-insulin in the 
medium was assessed as the proportion recovered in the supernatant 
following TCA precipitation. Data are means__+ S.E.M. of 3-4 separate 
experiments. (* * P < 0.01, * * * P < 0.001) 
crease in apparent receptor affinity (data not shown). How- 
ever, vanadate under the same conditions significantly 
inhibited in a concentration-dependent manner insulin 
binding to its receptor (by 61 + 7% in the presence of 10 
mM vanadate, n = 3, P < 0.05). Similarly, in experiments 
with partially purified insulin receptors, bpV(pic) again 
• 125 . . . . .  increased I-msuhn binding, whereas vanadate displayed 
an inhibitory effect (data not shown). 
3.4. Effects on insulin degradation 
cells indicating a time-dependent release of small amounts 
of insulin-degrading proteases from the cells (data not 
shown), bpV(pic) (1 mM) or vanadate (4 mM), when 
added to the cell-free medium, again clearly inhibited 
125I-insulin degradation (  = 3, P < 0.05, data not shown)• 
Furthermore, the ratio of degraded/intact intracellular 
le5I-insulin assessed in cells which had been trypsinized 
and solubilized after 1 h incubation with 125I-insulin in 
medium with 4% BSA, was reduced in a concentration-de- 
pendent manner following treatment with bpV(pic) or 
vanadate (Fig. 4). Bacitracin (1 mg/ml)  also inhibited the 
After 1 h incubation at 37°C, 125I-insulin degradation 
was not altered by bpV(pic) or vanadate in cell-free medium 
containing 1% or 4% BSA nor in medium with cells and 
4% BSA (data not shown). However, when adipocytes 
were incubated with 125I-insulin in medium containing 1% 
BSA, both bpV(pic) and vanadate in a concentration-de- 
pendent manner educed 125I-insulin degradation measured 
in the medium as TCA precipitability (Fig. 3). The propor- 
tion of degraded insulin was reduced from ~ 25% to 
~ 10% (P  < 0.01). The protease inhibitor bacitracin (1 
mg/ml)  [31,32] more markedly inhibited insulin degrada- 
tion in the medium (to ~ 5%) and no additive inhibitory 
effect was seen when bpV(pic) or vanadate was added 
together with bacitracin (data not shown). Control experi- 
ments showed that adding bpV(pic) (1 mM) or vanadate (4 
mM) to the medium at the end of the incubation period did 
not affect the TCA precipitability of 125I-insulin. 
Cells were also incubated at 37°C in medium with 1% 
BSA and no other additions. After different times, the 
medium was separated from the cells, 0.2 ng/ml  of 1251- 
insulin added to the cell-free medium and the incubation 
continued for 1 h at 37°C in the presence or absence of 
bpV(pic) or vanadate. ~zsI-insulin degradation i  the cell- 
free medium was a function of the preincubation time with 
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Fig. 4. Effects of bpV(pic) and vanadate on intracellular insulin degrada- 
tion. Cells were incubated with bpV(pic) (0 )  or vanadate (O)  as 
described in Fig. 3 but in medium containing 4% BSA. Then, cells were 
treated with KCN (2 mM) and transferred to 16°C and treated with 
trypsin for 10 min followed by the addition of trypsin inhibitor. After 
washing with fresh medium, cells were solubilized and the ratio of 
degraded/total insulin, representing internalized insulin, was determined. 
Data are means + S.E.M. of 3 (bpV(pic)) or 4 (vanadate) separate xperi- 
ments. 
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Table 1 
Effects of vanadate and bpV(pic) on 125I-IGF II degradation (% of total 
t25I-IGF II) 
Concentration (raM) 
Addition 0 0.01 0.1 1 l 0 
vanadate 14_+1 13_+2 13-+3 20+2 * * 17-+3 
bpV(pic) 41 _+3 * * 22+3 * 16-+3 ND 
The experiments were performed as in Fig. 3 except hat 125I-IGF II (0.2 
ng/ml) was added instead of 1:~sI-insulin. Data are means _+ S.E.M. of 
three separate xperiments. P < 0.05, * * P < 0.01 vs no addition, 
respectively. ND, not done. 
degradation of insulin within the cell (to ~ 20%), but the 
effect was less pronounced than that of bpV(pic) or vana- 
date. 
To test the relative specificity of the inhibitory effects 
bpV(pic) and vanadate, we also assessed their effects on 
the degradation of insulin produced by collagenase. Nei- 
ther bpV(pic) (1 raM) nor vanadate (4 raM) inhibited the 
effect of collagenase (1 mg/ml or 0.1 mg/ml) (data not 
shown). In addition, degradation of 125I-IGF-II during 
incubation with adipocytes in medium with 1% BSA at 
37°C for 1 h was not inhibited by either bpV(pic) or 
vanadate (Table 1). In fact, both bpV(pic) and vanadate at 
some concentrations markedly enhanced 125I-IGF-II degra- 
dation (Table 1). 
m 
O 
E 4 
O 
o .  
Ih ,- 3 
0 2 
- I  
o~ 
e- 
f t  
f o 
100 
._~ 
x 
~ 80 
E 
"6 
g 60 
~ 40 
._e 
_= 20 
A 
, / /  
0 0.001 0.01 0,1 1 10 
bpV(pic) (mM) 
B 
/ t  
0 1 10 100 1000 
Insulin (pU/ml) 
Fig. 5. A,B: Effects of insulin and bpV(pic) on t4C-3-0-methylglucose 
transport. A: Cells were preincubated at 37°C for 20 min with 1 U/ml  
adenosine deaminase and the indicated concentrations of bpV(pic). Then, 
the rate of 3-0-methylglucose Uansport was determined as described in 
Section 2. Data are from one representative experiment repeated 5 times. 
B: Cells were preincubated as in A but with the different concentrations 
of insulin in the absence (O) or presence of bpV(pic) (0.005 mM, I1) or 
(0.01 mM, • ). Data are means :[: S.E.M. of 3 -5 separate experiments and 
are expressed as % of maximal insulin effect. The absolute rate 
(amol/cell/s) for basal and ma,dmal insulin-stimulated Jac-3-0-methyl- 
glucose transport was: 0.5 + 0.2 and 4.2 + 0.8 for control cells, 0.9 + 0.3 
and 4.2+0.6 for bpV(pic) 0.005 mM and 2.0+0.3 and 4.0+ 1.0 for 
bpV(pic) 0.01 mM, respectively 
3.5. Effects of bpV(pic) on 3-O-methylglucose transport 
Fig. 5A shows that increasing concentrations of bpV(pic) 
enhanced the rate of 3-0-methylglucose transport (ECs0 
9 + 3 /zM; n = 5). However, the dose-response curve 
again tended to be biphasic. At a concentration f 0.1 mM, 
bpV(pic) reached its maximal effect (544 + 136% of basal 
transport, n = 5, P < 0.05), which was nearly equal to that 
of 1000/zU/ml of insulin (690 + 156%, n = 5, P < 0.05). 
The effect of bpV(pic) on insulin sensitivity was also 
investigated. The dose-response curve for insulin-stimu- 
lated glucose transport was shifted to the left in the 
presence of low concentrations of bpV(pic) (Fig. 5B). 
ECs0 for insulin was 32 _+ 6 /xU/ml, 13 _+ 4 /zU/ml and 
8 _+ 4 ~U/ml  for control cells and cells treated with 0.005 
mM or 0.01 mM bpV(pic), respectively (n = 3-5, P < 
0.05). 
4. D iscuss ion  
The present data show that vanadate and, more 
markedly, bpV(pic) increase 125I-insulin binding to intact 
rat adipocytes when the incubations are performed at 37°C 
under conditions of prevailing receptor cycling. Scatchard 
analysis suggest hat this increase is due to an enhanced 
receptor affinity. However, binding assays in intact cells 
incubated at 37°C with prevailing receptor cycling not only 
reflects binding to cell surface receptors. Changes in rates 
of internalization and recycling of ligand-receptor com- 
plexes as well as in ligand degradation may also be 
involved. However, experiments addressing these possibili- 
ties show that bpV(pic) and vanadate increased cell-associ- 
ated 125I-insulin by both an increased receptor binding at 
the cell surface and an accumulation of intracellular ra- 
dioactivity. Both bpV(pic) and vanadate increased in a 
concentration-dependent manner the ratio of intra- 
cellular/total cell-associated radioactivity, suggesting an 
enhanced internalization of ligand-receptor complexes. 
However, since insulin receptor distribution between the 
cell surface and cell interior, assessed by 12sI-insulin bind- 
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ing to solubilized cells, was not altered by either bpV(pic) 
or vanadate, the increased intracellular 125I-insulin repre- 
sents accumulation of ligand but not receptors. Further- 
more, even after pretreating cells with a powerful inhibitor 
of insulin receptor internalization, a peptide fragment de- 
rived from the MHC-I molecule [30], ¿25I-insulin binding 
was still markedly enhanced (~ 3-fold) in the presence of 
0.5 mM bpV(pic), showing that there is indeed an in- 
creased binding of insulin to the cell surface receptors. 
Taken together, the data show that the effect of both 
bpV(pic) and vanadate on insulin binding to intact cells is 
attributable toboth an intracellular accumulation of cell-as- 
sociated radioactivity and an increased cell-surface recep- 
tor affinity for the ligand. 
The direct interactions of bpV(pic) and vanadate with 
the insulin-receptor binding process were also investigated. 
After receptor cycling was stopped by cellular ATP deple- 
tion with KCN [25,33,34], cell-surface binding of 125I-in- 
sulin was measured, bpV(pic) again enhanced binding but 
much less than in cells which had not been energy-de- 
pleted. In contrast, vanadate xerted a direct, concentra- 
tion-dependent i hibitory effect on 125I-insulin binding to 
cell surface receptors. This effect of vanadate was also 
shown in a previous study [12] and it was also demon- 
strated with partially purified receptors, where bpV(pic) 
again slightly enhanced binding. The mechanisms for these 
divergent effects of bpV(pic) and vanadate on insulin 
binding to its receptor are currently unclear but are proba- 
bly associated with changes in the conformation of the 
insulin receptors. 
Insulin binding to its receptor is rapidly followed by 
receptor internalization [31,35,36]. Internalized ligand-re- 
ceptor complexes ubsequently dissociate in the endo- 
somes [36]. A large proportion of receptors then recycles 
to the cell surface, whereas a small fraction is degraded. 
The dissociated insulin is either degraded or remains in- 
tact, but in both cases, it is eventually released from the 
cell [31,36,37]. The observed increase of 125I-insulin accu- 
mulated inside the cell following bpV(pic) or vanadate 
treatment could thus be caused by inhibition of intra- 
cellular insulin degradation or an attenuated retroendocyto- 
sis of intact or degraded insulin from the cell. Marshall et 
al. [28] suggested a sorting mechanism where vanadate can 
shunt the traffic of insulin from retroendocytosis to a 
degradation pathway. In the present study, we examined 
effects of bpV(pic) and vanadate on insulin degradation, 
both intracellularly and in the surrounding medium. When 
cells were incubated in medium containing 4% BSA no 
apparent effect of these agents on insulin degradation i
the medium was observed. However, since a high concen- 
tration of BSA per se can prevent insulin degradation [38], 
and thus disguise the effects of bpV(pic) and vanadate, 
experiments were performed with medium containing 1% 
BSA. Under these conditions, both bpV(pic) and vanadate 
significantly inhibited 125I-insulin degradation i a concen- 
tration-dependent manner. 
The inhibitory effects of bpV(pic) and vanadate on 
insulin degradation were also seen when these agents were 
added to cell-free medium in which adipocytes had previ- 
ously been incubated. This indicates that proteases which 
had been released from the cells were directly inhibited by 
both bpV(pic) and vanadate. Furthermore, no additive 
effects were seen when bpV(pic) or vanadate was added 
together with bacitracin, suggesting a mechanism similar 
to that of bacitracin, i.e., inhibition of insulin-degrading 
enzymes [27,32,39]. Most importantly, vanadate and 
bpV(pic) decreased the proportion of intracellularly de- 
graded insulin. There was no inhibitory effect of bpV(pic) 
and vanadate on I25I-IGF-II degradation and, in addition, 
the degradation of insulin produced by collagenase was 
unaffected. Taken together, these findings indicate a rela- 
tively specific inhibitory effect of bpV(pic) and vanadate 
on intracellular insulin-degrading proteases. The mecha- 
nism for this inhibition is presently unclear, but one possi- 
bility may be the formation of vanadium complexes with a 
sulfhydryl protease, similar to the proposed vanadium 
interaction with PTP's by complexing with cystein in the 
active enzyme centre [18]. 
The dose-response curve for the effects of bpV(pic) on 
binding and degradation are clearly different; biphasic vs 
monophasic and different ECs0 (~ 0.06 mM vs ~ 1.5 
mM). Moreover, the stimulatory effect of bpV(pic) on 
glucose transport had an even lower ECs0 (~ 9/zM) than 
the other effects. This suggests that different mechanisms 
are involved. The higher sensitivity to bpV(pic) than to 
vanadate is explained by the 10- to 100-fold greater po- 
tency of bpV(pic) to inhibit PTP's [23]. This effect can 
also enhance insulin action, since insulin-stimulated recep- 
tor kinase activity is amplified when receptor-associated 
PTP's are inhibited by pV or vanadate [23]. However, the 
ability of bpV(pic) and vanadate to enhance insulin sensi- 
tivity also seems related to their ability to enhance insulin 
binding. Moreover, the demonstrated inhibition of insulin 
degradation may lead to a prolonged signalling along the 
cellular itinerary of insulin-receptor complexes, and thus 
contribute to an increased insulin sensitivity. 
In conclusion, the present work shows that the peroxo- 
vanadium compound bpV(pic) and, to a lesser degree, 
vanadate can increase insulin binding to intact rat fat cells, 
mainly due to an increased apparent receptor affinity. 
bpV(pic) and vanadate also displayed a relatively specific 
inhibition of intracellular insulin-degrading proteases. 
Moreover, low concentrations of bpV(pic), similar to pre- 
vious findings with vanadate [12], enhanced the cellular 
sensitivity to insulin action on glucose transport. 
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